NICE approves DRF-funded treatment for Duchenne

New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...

World Muscle Society awards 2024 DRF prize

The World Muscle Society has awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 29th congress in Prague, Czech Republic, in October 2024 was Rebecca Willcocks,...

Vamorolone approved in the UK

The Duchenne Reserach Fund is delighted to share that the MHRA (Medicines and Healthcare products Regulatory Agency) has approved vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. This is a significant...

Vamorolone approved in the US

The US FDA (Food and Drug Administration) has approved Vamorolone for the treatment of Duchenne muscular dystrophy in children and adults aged 2 and over. It will be sold under the brand name Agamree and is expected to be available in the US in early 2024. This...

DRF-funded drug shows success in clinical trial

We are pleased to share that Vamorolone, an alternative medicine to corticosteroids, has shown positive results in a Phase 2 Study. Vamorolone was developed as a treatment for Duchenne muscular dystrophy, to offer the benefits of steroids, but without some of the side...

ReveraGen receives $3.3m NIH grant for Vamorolone

ReveraGen BioPharma has received a $3.3 million grant from the NIH – the US National Institutes of Health – for their ongoing work on the steroid alternative treatment Vamorolone for Duchenne muscular dystrophy. The NIH Commercialization Readiness Pilot...

Two-year Vamorolone study completed

Santhera Pharmaceuticals has announced that partner ReveraGen Biopharma has completed a long-term, open-label extension study of 24 months duration with Vamorolone in patients with Duchenne muscular dystrophy. Including 6 months treatment in the preceding study,...

ReveraGen BioPharma licenses option to develop Vamorolone with Actelion

We’re sharing news that ReveraGen BioPharma has licensed an option to develop Vamorolone with Actelion Ltd. Vamorolone is the first in-human steroid like compound that has shown in animal models to have many of the benefits of corticosteroids, without the many side...